AI assistant
Sending…
Barinthus Biotherapeutics plc. — Director's Dealing 2021
Apr 30, 2021
34488_dirs_2021-04-29_45b0ea87-f1a6-4c40-b791-847c78d75834.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Vaccitech plc (VACC)
CIK: 0001828185
Period of Report: 2021-04-29
Reporting Person: Marshall Margaret (Chief Medical Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Share Option (Right to Buy) | $0.0004 | 2030-11-02 | Ordinary Shares (88065) | Direct |
Footnotes
F1: This option shall vest and become exercisable in four equal annual installments, with the first installment vesting on November 2, 2021. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3662 to GBP 1.00 on December 31, 2020.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
More from Barinthus Biotherapeutics plc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 21
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Board/Management Information
2026
Apr 22
M&A Activity
2026
Feb 23
Delisting Announcement
2026
Jan 6
Regulatory Filings
2025
Dec 10
Interim / Quarterly Report
2025
Nov 7
Earnings Release
2025
Nov 7
M&A Activity
2025
Sep 30